Wave Life Sciences Ltd. (WVE)
NASDAQ: WVE
· Real-Time Price · USD
7.92
0.20 (2.59%)
At close: May 01, 2025, 3:59 PM
2.59% (1D)
| Bid | 7.55 |
| Market Cap | 1.22B |
| Revenue (ttm) | 108.3M |
| Net Income (ttm) | -97.01M |
| EPS (ttm) | -0.7 |
| PE Ratio (ttm) | -11.32 |
| Forward PE | -7.92 |
| Analyst | Buy |
| Ask | 8.35 |
| Volume | 1,497,404 |
| Avg. Volume (20D) | 1,280,550 |
| Open | 7.54 |
| Previous Close | 7.72 |
| Day's Range | 7.43 - 8.05 |
| 52-Week Range | 4.25 - 16.74 |
| Beta | -0.94 |
About WVE
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company also develops WVE-004, a C9orf72 molecule for the t...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 11, 2015
Employees 287
Stock Exchange NASDAQ
Ticker Symbol WVE
Website https://www.wavelifesciences.com
Analyst Forecast
According to 12 analyst ratings, the average rating for WVE stock is "Buy." The 12-month stock price forecast is $22, which is an increase of 177.60% from the latest price.
Stock ForecastsNext Earnings Release
Wave Life Sciences Ltd. is scheduled to release its earnings on May 8, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 day ago
+7.47%
Wave Life Sciences shares are trading higher after...
Unlock content with
Pro Subscription
1 month ago
+6.14%
Wave Life Sciences shares are trading higher after the company announced its Phase 2 DMD trial results.
